山东大学耳鼻喉眼学报 ›› 2022, Vol. 36 ›› Issue (5): 106-112.doi: 10.6040/j.issn.1673-3770.0.2021.374

• 综述 • 上一篇    

安罗替尼联合治疗在肿瘤治疗中的研究进展

宋晴1,2,3综述 宋西成2,3,4审校   

  1. 1. 潍坊医学院 临床医学院, 山东 潍坊 261032;
    2. 青岛大学附属烟台毓璜顶医院 耳鼻咽喉头颈外科, 山东 烟台 264000;
    3. 青岛大学附属烟台毓璜顶医院 耳鼻咽喉实验室, 山东 烟台 264000;
    4. 山东省耳鼻喉疾病临床医学研究中心, 山东 烟台 264000
  • 发布日期:2022-09-20
  • 通讯作者: 宋西成. E-mail:songxicheng@126.com
  • 基金资助:
    泰山学者工程资助项目(20190991)

Research progress of anlotinib combination therapy in cancer treatment

SONG Qing1,2,3Overview,SONG Xicheng2,3,4Guidance   

  1. 1. Department of Weifang Medical University, Clinical Medical College, Weifang 261032, Shandong, China;
    2. Department of Otorhinolaryngology & Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, Shandong, China;
    3. Department of Otorhinolaryngology Laboratory, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, Shandong, China;
    4. Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai 264000, Shandong, China
  • Published:2022-09-20

PDF (PC)

193

摘要： 安罗替尼是一种多靶点酪氨酸激酶抑制剂,可以通过调节肿瘤内血管的生成或改变免疫抑制微环境,发挥其抗肿瘤作用。安罗替尼已批准应用于非小细胞肺癌、软组织肉瘤、小细胞肺癌等多种类型肿瘤的临床治疗,并且在部分晚期或复发的患者取得一定治疗效果。多项临床研究发现安罗替尼与化疗、放疗、免疫检查点抑制剂等联合治疗可以显著抑制肿瘤,其治疗效果明显优于安罗替尼单药应用。论文对安罗替尼的作用机制及其在肿瘤中的联合治疗研究进展进行综述。

关键词: 安罗替尼, 联合用药, 肿瘤治疗, 抗血管生成, 免疫微环境

Abstract: Anlotinib is a multi-targeting tyrosine kinase inhibitor that can play an anti-tumor role by regulating angiogenesis in cancer or an immunosuppressive microenvironment. Anlotinib shows therapeutic effects in patients with advanced or recurrent cancer and has been approved for the clinical treatment of non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer, medullary thyroid cancer, and other types of tumors. Clinical studies have found that anlotinib combined with chemotherapy, radiotherapy, and immune-checkpoint inhibitors could inhibit tumor growth and showed significantly better therapeutic effects than anlotinib monotherapy. In this article, we review the mechanism of action of anlotinib and the progress in research on anlotinib in combination with other cancer treatments.

Key words: Anlotinib, Combination medication, Cancer treatment, Antiangiogenesis, Immune microenvironment

中图分类号: 

  • R73
[1] Shen GS, Zheng FC, Ren DF, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. J Hematol Oncol, 2018, 11(1): 120. doi:10.1186/s13045-018-0664-7.
[2] Xie CY, Wan XZ, Quan HT, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci, 2018, 109(4): 1207-1219. doi:10.1111/cas.13536.
[3] Tiseo M, Franciosi V, Ardizzoni A. Multi-target inhibitors in non-small cell lung cancer(NSCLC)[J]. Ann Oncol, 2006, 17(Suppl 2): ii55-ii57. doi:10.1093/annonc/mdj924.
[4] Takahashi S. Vascular endothelial growth factor(VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy[J]. Biol Pharm Bull, 2011, 34(12): 1785-1788. doi:10.1248/bpb.34.1785.
[5] Song F, Hu B, Cheng JW, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma[J]. Cell Death Dis, 2020, 11(7): 573. doi:10.1038/s41419-020-02749-7.
[6] Tang XL, Zheng Y, Jiao DM, et al. Anlotinib inhibits cell proliferation, migration and invasion via suppression of c-met pathway and activation of ERK1/2 pathway in H446 cells[J]. Anticancer Agents Med Chem, 2021, 21(6): 747-755. doi:10.2174/1871520620666200718235748.
[7] Lin BY, Song XM, Yang DW, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. Gene, 2018, 654: 77-86. doi:10.1016/j.gene.2018.02.026.
[8] Yang Q, Ni LC, Imani S, et al. Anlotinib suppresses colorectal cancer proliferation and angiogenesis via inhibition of AKT/ERK signaling cascade[J]. Cancer Manag Res, 2020, 12: 4937-4948. doi:10.2147/CMAR.S252181.
[9] Qin TT, Liu ZJ, Wang J, et al. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling[J]. Cancer Biol Med, 2020, 17(3): 753-767. doi:10.20892/j.issn.2095-3941.2020.0024.
[10] Liang HG, Wang MZ. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer[J]. Cancer Manag Res, 2019, 11: 7707-7719. doi:10.2147/CMAR.S212238.
[11] Liu SC, Qin TT, Liu ZJ, et al. Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells[J]. Cell Death Dis, 2020, 11(5): 309. doi:10.1038/s41419-020-2511-3.
[12] Shi JZ, Zhang YJ, Wang JZ, et al. Anlotinib combined with chemoradiotherapy exhibits significant therapeutic efficacy in esophageal squamous cell carcinoma[J]. Front Oncol, 2020, 10: 995. doi:10.3389/fonc.2020.00995.
[13] Yang YL, Li L, Jiang ZS, et al. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer[J]. Cancer Immunol Immunother, 2020, 69(12): 2523-2532. doi:10.1007/s00262-020-02641-5.
[14] Liu YC, Wu L, Tong RZ, et al. PD-1/PD-L1 inhibitors in cervical cancer[J]. Front Pharmacol, 2019, 10: 65. doi:10.3389/fphar.2019.00065.
[15] Deng ZM, Liao W, Wei W, et al. Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe[J]. Cancer Cell Int, 2021, 21(1): 37. doi:10.1186/s12935-020-01721-x.
[16] Gao Q, Jiang YQ, Li XJ, et al. Intratumoral injection of anlotinib hydrogel combined with radiotherapy reduces hypoxia in lewis lung carcinoma xenografts: assessment by micro fluorine-18-fluoromisonidazole positron emission tomography/computed tomography hypoxia imaging[J]. Front Oncol, 2021, 11: 628895. doi:10.3389/fonc.2021.628895.
[17] Guo L, Zhang LY, Guan Y, et al. In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy[J]. Thorac Cancer, 2021, 12(5): 593-602. doi:10.1111/1759-7714.13780.
[18] Wang GY, Sun MX, Jiang YF, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma[J]. Int J Cancer, 2019, 145(4): 979-993. doi:10.1002/ijc.32180.
[19] Zhao D, Xie B, Yang Y, et al. Progress in immunotherapy for small cell lung cancer[J]. World J Clin Oncol, 2020, 11(6): 370-377. doi:10.5306/wjco.v11.i6.370.
[20] 陈曦, 乔明哲. 免疫检查点抑制剂在复发或转移性头颈鳞癌的治疗进展[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 42-48. doi: 10.6040/j.issn.1673-3770.1.2019.001. CHEN Xi, QIAO Mingzhe. Progress of immune checkpoint inhibitors in the treatment of recurrent or metastatic head and neck squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(3): 42-48. doi: 10.6040/j.issn.1673-3770.1.2019.001.
[21] Li T, Qian YX, Zhang CF, et al. Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo[J]. Transl Lung Cancer Res, 2021, 10(4): 1873-1888. doi:10.21037/tlcr-21-192.
[22] Liu JY, Fan ZF, Li S, et al. Target therapy for metastatic alveolar soft part sarcoma: a retrospective study with 47 cases[J]. Ann Transl Med, 2020, 8(22): 1493. doi:10.21037/atm-20-6377.
[23] Long ZY, Lu YJ, Li MH, et al. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review[J]. Ann Palliat Med, 2021, 10(6): 7073-7082. doi:10.21037/apm-20-1790.
[24] Han BH, Li K, Wang QM, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncol, 2018, 4(11): 1569-1575. doi:10.1001/jamaoncol.2018.3039.
[25] Zhou AP, Bai YX, Song Y, et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial[J]. Oncologist, 2019, 24(8): e702-e708. doi:10.1634/theoncologist.2018-0839.
[26] He ZL, Liu J, Ma YW, et al. Anlotinib combined with cranial radiotherapy for non-small cell lung cancer patients with brain metastasis: a retrospectively, control study[J]. Cancer Manag Res, 2021, 13: 6101-6111. doi:10.2147/CMAR.S319650.
[27] Zhu X, Tao H, Kong C, et al. 1386P Anlotinib combined with whole brain radiation therapy(WBRT)for advanced non-small cell lung cancer with multiple brain metastases: an open-label, single-arm phase II trial[J]. Ann Oncol, 2020, 31: S881. doi:10.1016/j.annonc.2020.08.1700.
[28] Kong C, Zhu X, Jiang M, et al. Anlotinib in combination with whole brain radiotherapy for advanced non-small-cell lung cancer with brain metastases progressive or developed after at least one lines of prior treatment[J]. Int J Radiat Oncol, 2021, 111(3): e569. doi:10.1016/j.ijrobp.2021.07.1537.
[29] Chai PW, Zhou CD, Jia RB, et al. Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report[J]. Diagn Pathol, 2020, 15(1): 2. doi:10.1186/s13000-019-0922-1.
[30] Jang HS, Woo SR, Song KH, et al. API5 induces cisplatin resistance through FGFR signaling in human cancer cells[J]. Exp Mol Med, 2017, 49(9): e374. doi:10.1038/emm.2017.130.
[31] Sugimoto K, Miyata Y, Nakayama T, et al. Fibroblast Growth Factor-2 facilitates the growth and chemo-resistance of leukemia cells in the bone marrow by modulating osteoblast functions[J]. Sci Rep, 2016, 6: 30779. doi:10.1038/srep30779.
[32] Gao Y, Liu PF, Shi RH. Anlotinib as a molecular targeted therapy for tumors[J]. Oncol Lett, 2020, 20(2): 1001-1014. doi:10.3892/ol.2020.11685.
[33] Wang HY, Chu JF, Zhang P, et al. Safety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in Chinese patients with advanced/metastatic soft tissue sarcoma[J]. Onco Targets Ther, 2020, 13: 1561-1568. doi:10.2147/OTT.S235349.
[34] Ni J, Cheng XZ, Chen J, et al. Anlotinib as exploratory therapy for platinum-resistant ovarian cancer: a retrospective study on efficacy and safety[J]. Onco Targets Ther, 2020, 13: 9857-9863. doi:10.2147/OTT.S268613.
[35] Wang HY, Chu JF, Zhao Y, et al. A trial of the safety and efficacy of chemotherapy plus anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer[J]. Cancer Manag Res, 2020, 12: 3827-3834. doi:10.2147/CMAR.S249678.
[36] Chu TQ, Zhong RB, Zhong H, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC[J]. J Thorac Oncol, 2021, 16(4): 643-652. doi:10.1016/j.jtho.2020.11.026.
[37] Yang SJ, Zhang WJ, Chen Q, et al. Clinical investigation of the efficacy and safety of anlotinib with immunotherapy in advanced non-small cell lung cancer as third-line therapy: a retrospective study[J]. Cancer Manag Res, 2020, 12: 10333-10340. doi:10.2147/CMAR.S280096.
[38] Chen Y, Yang ZY, Wang YN, et al. Pembrolizumab plus chemotherapy or anlotinib vs. pembrolizumab alone in patients with previously treated EGFR-mutant NSCLC[J]. Front Oncol, 2021, 11: 671228. doi:10.3389/fonc.2021.671228.
[39] Yuan M, Fang JM, Zhu ZZ, et al. The clinical activity and safety of anlotinib combined with anti-PD-1 antibodies in patients with advanced solid tumors[J]. J Clin Oncol, 2020, 38(15_suppl): e15081. doi:10.1200/jco.2020.38.15_suppl.e15081.
[40] Wang YN, Zhang QN, Miao LY, et al. Nivolumab in combination with anlotinib achieved remarkable efficacy in a patient with driver-negative lung squamous cell carcinoma and PS of 4[J]. Ann Palliat Med, 2020, 9(6): 4384-4388. doi:10.21037/apm-20-2096.
[41] Jiang M, Zhang XC. Antiangiogenesis combined with immunotherapy to treat advanced small-cell carcinoma of the esophagus resistant to chemotherapy: according to the guidance of next-generation sequencing[J]. Onco Targets Ther, 2021, 14: 1613-1621. doi:10.2147/OTT.S293733.
[42] She L, Su L, Shen LF, et al. Retrospective study of the safety and efficacy of anlotinib combined with dose-dense temozolomide in patients with recurrent glioblastoma[J]. Front Oncol, 2021, 11: 687564. doi:10.3389/fonc.2021.687564.
[43] Zhai CY, Zhang XL, Ren LL, et al. The efficacy and safety of anlotinib combined with PD-1 antibody for third-line or further-line treatment of patients with advanced non-small-cell lung cancer[J]. Front Oncol, 2020, 10: 619010. doi:10.3389/fonc.2020.619010.
[1] 李静静, 武欣欣, 毛宁, 郑桂彬, 牟亚魁, 初同朋, 贾传亮, 郑海涛, 米佳, 宋西成. 基于CT影像组学诺模图术前预测甲状腺乳头状癌颈部中央区淋巴结转移的研究[J]. 山东大学耳鼻喉眼学报, 2021, 35(4): 51-59.
[2] 韩继波,邹游,杨蕊,陶泽璋. Notch受体调控上皮-间质转化对鼻咽癌细胞顺铂耐药的影响[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 105-110.
[3] 王莹莹,张立庆,周涵,董诗坤,陈海兵,陈曦,董伟达. 74例鳃裂囊肿及瘘管临床分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 111-116.
[4] 于克娜,孙凯月,张杰,金鹏. 西妥昔单抗治疗头颈部鳞状细胞癌差异表达基因的生物信息学分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 117-124.
[5] 潘新良. 加强甲状腺结节及恶性肿瘤的规范治疗[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 1-12.
[6] 宋西成, 郑海涛. 甲状旁腺自荧光显影技术应用研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 19-25.
[7] 青晓艳, 徐义全综述李超审校. 甲状腺未分化癌的分子机制研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 26-31.
[8] 武欣欣, 李静静, 毛宁, 郑桂彬, 郑海涛, 崔景景, 贾传亮, 初同朋, 牟亚魁, 宋西成. 基于CT影像组学诺模图预测微小甲状腺结节良恶性[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 32-39.
[9] 陈海兵, 卫亚楠, 许晓泉, 陈曦. 基于XGBoost人工智能结合CT构建甲状腺癌颈部淋巴结转移预测模型[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 40-45.
[10] 邓迪, 刘均, 李林珂, 王吉, 刘吉峰, 吕丹, 王海洋, 甘卫刚, 王君, 李波, 陈飞. 皮瓣二期重建策略应用于气管非环周缺损修复重建[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 52-57.
[11] 郑桂彬, 张国军, 马驰, 韦树建, 孙海清, 吴国长, 郭雅文, 郑海涛, 宋西成. 经口腔前庭入路腔镜甲状腺手术在甲状腺乳头状癌中的安全效用分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 58-63.
[12] 房忠菊, 张永侠, 赵建东, 纵亮, 翟性友, 李新建, 彭新, 任楠, 陈立伟, 刘明波. 甲状腺癌颈清扫术后乳糜漏的综合治疗[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 64-68.
[13] 黄乃思, 马奔, 官青, 王蕴珺, 魏文俊, 卢忠武, 杨舒雯, 徐伟博, 向俊, 嵇庆海, 王宇. 侧颈部淋巴结示踪技术在甲状腺癌手术治疗中的应用[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 69-74.
[14] 王佳说, 郭星, 阎艾慧. 甲状腺乳头状癌颈淋巴结转移形成巨大囊性变的诊断总结[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 111-113.
[15] 汪茂林, 李菊兰, 鲜昆仑. 继发性甲旁亢甲状旁腺切除不同移植方案疗效研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 114-119.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发